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Abstract
Improved molecular diagnostic methods for detection drug resistance inMycobacterium tu-
berculosis (MTB) strains are required. Resistance to first- and second- line anti-tuberculous
drugs has been associated with single nucleotide polymorphisms (SNPs) in particular
genes. However, these SNPs can vary between MTB lineages therefore local data is re-
quired to describe different strain populations. We used whole genome sequencing (WGS)
to characterize 37 extensively drug-resistant (XDR) MTB isolates from Pakistan and investi-
gated 40 genes associated with drug resistance. Rifampicin resistance was attributable to
SNPs in the rpoB hot-spot region. Isoniazid resistance was most commonly associated with
the katG codon 315 (92%) mutation followed by inhA S94A (8%) however, one strain did
not have SNPs in katG, inhA or oxyR-ahpC. All strains were pyrazimamide resistant but
only 43% had pncA SNPs. Ethambutol resistant strains predominantly had embB codon
306 (62%) mutations, but additional SNPs at embB codons 406, 378 and 328 were also
present. Fluoroquinolone resistance was associated with gyrA 91–94 codons in 81% of
strains; four strains had only gyrBmutations, while others did not have SNPs in either gyrA
or gyrB. Streptomycin resistant strains had mutations in ribosomal RNA genes; rpsL codon
43 (42%); rrs 500 region (16%), and gidB (34%) while six strains did not have mutations in
any of these genes. Amikacin/kanamycin/capreomycin resistance was associated with
SNPs in rrs at nt1401 (78%) and nt1484 (3%), except in seven (19%) strains. We estimate
that if only the common hot-spot region targets of current commercial assays were used,
the concordance between phenotypic and genotypic testing for these XDR strains would
vary between rifampicin (100%), isoniazid (92%), flouroquinolones (81%), aminoglycoside
(78%) and ethambutol (62%); while pncA sequencing would provide genotypic resistance
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in less than half the isolates. This work highlights the importance of expanded targets for
drug resistance detection in MTB isolates.
Introduction
Mycobacterium tuberculosis (MTB) caused 9 million cases of tuberculosis (TB) and 1.5 million
death worldwide in 2013 [1]. Drug resistance in MTB increases the burden due to the disease
and complicates both diagnosis and treatment. Multidrug-resistant (MDR)-TB is caused by
MTB resistant to at least the two first line drugs i.e. rifampicin and isoniazid. Globally, in 2013,
an estimated 480,000 people developed TB while, there were about 210,000 deaths due to TB
[1]. Extensively drug resistant (XDR)-TB is caused by MDR-TB strains resistant to fluoroquin-
olone and to any one of the injectable aminoglycosides; amikacin, kanamycin or capreomycin.
In Pakistan, MDR-TB comprises 4–5% of all TB cases, and XDR-TB is 4–5% of the MDR-TB
cases [2,3]. Appropriate MDR-TB management requires drug susceptibility testing to guide
treatment regimens. The usual turnaround time for phenotypic MTB drug susceptibility testing
(DST) is about 8–10 weeks, often leading to delays in initiation of appropriate therapy. In high
TB burden low resource settings facilities for mycobacterial culture and DST are limited.
Therefore, rapid genotypic methods for detection of drug resistant MTB strains are required
for more effective management of TB.
The Xpert MTB/RIF assay (Cepheid, USA) assay was rolled out at a global level since 2012;
it detects rifampicin resistance by targeting the ribosomal polymerase rpoB gene [4]. The LiPA
MTBDRplus (Hain Lifescience GmbH, Germany) assay targets rpoB for rifampicin resistance
and katG and inhA genes for isoniazid resistance. The LiPA MTBDRsl (Hain Lifescience
GmbH, Germany) targets gyrA, rrs and embB for fluoroquinolone, aminoglycoside and etham-
butol resistance respectively [5]. Whilst these assays have significant value and allow rapid di-
agnosis of MDR-TB it is apparent that further improvements in molecular DSTs are required.
MTB is largely clonal [6,7]. The TBDReaM database (http://www.tbdreamdb.com), catalogues
greater than 1400 SNPs associated with drug resistance [8]. Studies of drug resistant MTB have
shown that mutations in hot- spot regions, and those occurring beyond hypervariable regions
vary according to both strain type and geographical location [9,10,11]. Thus, it is important for
all possible resistance conferring mutations or single nucleotide polymorphisms (SNPs) related
to each anti-tuberculous drug to be identified. Whole genome sequencing (WGS) facilitates the
identification of SNPs, insertions and deletions in genomic DNA [12]. Thus, WGS of MTB can
reveal new SNPs in genes previously associated with drug resistance and also identify outbreak
strains [13].
By providing information on multiple genes simultaneously WGS facilitates the under-
standing of relationships between genes and their interactions such as in the case of fitness con-
ferring compensatory mutations which occur due to the presence of drug induced selection
pressure. Compensatory mutations are believed to play a role in conferring fitness to drug re-
sistant MTB strains by affecting the growth rate of the isolates [14,15,16]. Compensatory muta-
tions in rpoB genes which aid fitness of rifampicin resistant strains are well documented [17].
Knowledge of additional resistance mutation and compensatory mutations in MTB will be im-
portant for determining appropriate treatment for MTB strains. Here we have used WGS anal-
ysis to describe XDR-TB strains from Pakistan and identify SNPs in genes known to be
associated with drug resistance to particular drugs.
Drug Resistance Conferring Mutations in XDR TB Strains from Pakistan
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Materials and Methods
Ethics statement
This study was approved by the Ethical Review Committee, The Aga Khan University.
Strain selection
TheM. tuberculosis strains studied were those collected from 2004–2009. Mycobacterial strains
were obtained from the strain bank of Aga Khan University Clinical Microbiology laboratory.
Demographic information on patients was obtained from clinical laboratory records and col-
lected as part of good clinical practice. The hospital and its clinical laboratory are accredited by
the Joint Commission of International Accreditation (JCIA, USA). MTB isolates were identi-
fied through a random selection method. Each strain had its unique identification number
which at the time of testing was anonymised and unlinked with patient demographic informa-
tion. The XDR-TB (n = 37) and drug susceptible (n = 5) isolates studied here were spoligotyped
previously [3].
Spoligotyping
Spoligotype patterns for each strain were obtained as described previously [18], and also con-
firmed in silico from the sequencing reads using SpolPred software [19].
Culture and drug susceptibility testing
M. tuberculosis strains were isolated from Lowenstein-Jensen media and MGIT (Becton Dick-
inson, Franklin Lakes, NJ, and USA).M. tuberculosis was identified using BACTEC NAP TB
differentiation test (Becton Dickinson), growth on para-nitrobenzoic acid containing media,
nitrate reduction, and niacin accumulation [20]. DST of these isolates was performed using an
agar proportion method on enriched Middlebrook 7H10 medium (BBL Microbiology Systems,
Cockeysville, MD, USA) at the following concentrations: rifampicin 1 μg/mL, isoniazid 0.2 μg/
mL, streptomycin 2 μg/mL, and ethambutol 5 μg/mL. Pyrazinamide sensitivity was determined
by using BACTEC 7H12 medium, pH 6.0, at 100 μg/mL (BACTEC PZA test medium, Becton
Dickinson). MDR TB strains were further tested with ciprofloxacin 2 μg/mL, capreomycin
10 μg/mL, amikacin 5μg/mL, kanamycin 6μg/mL and ethionamide 5 μg/mL. The reference
strainM. tuberculosisH37Rv was used as a control with each susceptibility testing batch [21].
DNA extraction andWhole Genome Sequencing of MTB isolates
DNA was extracted by the cetyl-trimethyl ammonium bromide (CTAB) method [22]. One mi-
crogram of DNA was used for sequencing. All samples underwent WGS with 76-base paired
end fragment sizes, using Illumina paired end HiSeq2000 technology, and the raw sequence
data is available in the European nucleotide archive (http://www.ebi.ac.uk/ena/data/view/
PRJEB7798). For each sample trimmomatic software (http://www.usadellab.org/cms/?page=
trimmomatic) was used to remove low quality reads and trim low-quality 3’ ends of reads. Nu-
cleotide positions in the reads with a quality score lower than Q20 were removed. High quality
reads were then mapped to the H37Rv reference genome (Genbank accession: AL123456.3)
using BWA-MEM software (http://bio-bwa.sourceforge.net). SAMtools (http://samtools.
sourceforge.net) and GATK (https://www.broadinstitute.org/gatk) were used to call single nu-
cleotide polymorphisms (SNPs) and small indels. Variants (with quality at least Q30) were
then selected as the intersection dataset between those obtained from both programs. Sample
genotypes were called using the majority allele (minimum frequency 75%) in positions sup-
ported by at least 20-fold total coverage; otherwise they were classified as missing. Samples
Drug Resistance Conferring Mutations in XDR TB Strains from Pakistan
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with a proportion of missing genotype calls greater than 15% were filtered out [21]. Similarly,
we excluded positions in the genome with more than 15% missing genotypes across samples.
Larger indels were called using a consensus from paired end mapping distance or split read ap-
proaches [23,24,25,26]. For more detail, the data processing pipeline has been described [27].
Spoligotypes were inferred from the sequencing reads SpolPred software [19]. Variation density
maps were generated using Circos software (http://www.circos.com).
Single nucleotide polymorphisms (SNPs)
The SNP data obtained was analysed according to known resistance conferring genes for each
anti-tuberculous drug. For rifampicin resistance, rpoB, rpoA and rpoC were analysed. For iso-
niazid resistance, katG, inhA,oxyR-ahpC, fpbC, Rv1592C, Rv1772, Rv2242, fabD, kasA, accD,
oxyR, ndh, fadE24, and nat were investigated. For pyrazinamide resistance, the pncA and rpsA
genes were studied. For ethambutol resistance, embC, embA, embB, embR, iniA, iniB, iniC,
Rv3124,manB, PPE49 and rmlD genes were studied. For streptomycin resistance, rpsL, rrs and
gidB genes were investigated. For flouroquinolone resistance, gyrA and gyrB genes were stud-
ied. For aminoglycoside resistance, rrs and tlyA, and for ethionamide resistance ethA and
fabG1 genes were analysed. SNPs were divided into synonymous (sSNPs) and non-synony-
mous (ns-SNPs) mutations. Each SNP was compared with that listed in TBDReaMDB (http://
www.tbdreamdb.com) database and other published reports of drug resistant MTB genotypes.
For each strain, genotypic drug resistance findings were compared with phenotypic drug
susceptibility results.
Phylogenetic analysis
Phylogenetic analysis was performed in PHYLIP using a RAxML tree (Maximum likelihood
phylogenetic software) with bootstrap to 1000 replicated [28]. Phylogenetic tree was visualized
using Dendroscope software [29].
Results
Demographic information, phenotypic drug susceptibility and genotypic
profile
The XDR strains comprised mainly CAS family isolates: CAS1-Delhi (n = 20), CAS (n = 2) and
CAS2 (n = 1). Other strains belonged to EAT3-IND (n = 2), X3 (n = 1), T1 (n = 3) and Orphan
(n = 8) lineages. Drug susceptible isolates were CAS1-Delhi (n = 2) and CAS (n = 3) strains.
The XDR strains were from the four provinces of Pakistan; Sindh (n = 21), Punjab (n = 16),
Khyber Pakhtunkhwa Province (n = 4) and Baluchistan (n = 1), S1 Dataset. Sixty-two percent
(n = 26) of MTB isolates were from males and 32% (n = 16) from females. The mean and medi-
an ages of patients was 34.2 and 31 years respectively (males: mean, 36.2, median, 34.5; female:
mean 31.1, median, 26 years).
Isolates from Sindh comprised Central Asian Strain (CAS), T1, East African Indian (EAI),
X and Orphan types and thus had more diverse lineages as compared to those from other prov-
inces. However, within each province the CAS lineage was predominant, as described previous-
ly [30].
Shared type spoligotypes and unique MTB isolates were linked to their respective principal
genetic group (PGG) based on the combinations of katG463-gyrA95 polymorphism [31], S1
Dataset and S2 Dataset. Most of the strain types (90.5%, 38/42) except, X3 (n = 1) and T1
(n = 3) belonged to the PGG1 lineage (based on katG codon 463 CTG (Leu) and gyrA codon
95 ACC (Thr) polymorphisms). PGG1 strains included CAS, EAI and Orphan strains. One,
Drug Resistance Conferring Mutations in XDR TB Strains from Pakistan
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X3 isolate was grouped in PGG2 as it showed katG 463 CGG (Arg) and gyrA codon 95 ACC
(Thr) polymorphism. Three T1 isolates with katG 463 CGG (Arg) and gyrA codon 95 AGC
(Ser) mutations were grouped in PGG3.
Polymorphisms in genes associated with drug resistances
A visual description of SNPs densities throughout the genome of MTB isolates was compiled
by a circos plot (Fig. 1). The maximum likelihood analysis is demonstrated by the circular
phlyogenetic tree based on the polymorphism in the drug resistance genes using Dendroscope
software version 3.2.8 [32], (Fig. 2). The clustering pattern of the strains demonstrated that T1
and X lineage strains clustered together (PGG3 and PGG2 groups respectively), and were dis-
tinct from CAS and EAI strains which clustered in a similar node. However, EAI remained dis-
tant from other PGG1 isolates in the phylogenetic tree.
By comparison with the H37Rv reference genome, SNPs were identified in 40 genes associ-
ated with drug resistance (Fig. 3). All synonymous SNPs (sSNPs) were removed from the anal-
ysis so that only non-synonymous SNPs (nsSNPs) are displayed in S2 Dataset. This nsSNP
dataset is further described in Tables 1–5, which focus on the known resistance-determining
regions in particular MTB genes.
Polymorphisms conferring rifampicin and isoniazid resistance
Resistance to rifampicin is associated with mutations in the RNA polymerase gene sub-unit B,
rpoB. However, there is a fitness cost associated with the acquistion of rpoB mutation and ri-
fampicin resistant MTB strains often acquire compensatory mutations in rpoC and rpoA genes
to their improve growth [33]. Similarly, there is a fitness cost associated with acquisition of iso-
niazid resistance, and while katG followed by the inhA gene mutations are most common, a
number of other genes are thought to contribute to resistance [34]. We first evaluated SNPs in
the context of MDR by studying the rifampicin-resistance determining region (RRDR) in rpoB,
and compensatory mutations in rpoC and rpoA. For isoniazid resistance we analysed the katG
and inhA genes, and also investigated sequences of oxyR-ahpC, fbpC, Rv1592C, ndh, Rv2242,
fabD, accD, fad E24 and nat. Combinations of mutations observed in the XDR strains related
to rifampicin and isoniazid are illustrated in Table 1. All the XDR isolates exhibited mutations
in the RRDR of rpoB gene; codons 531 (n = 24), 516 (n = 12) and 526 (n = 1). The rpoB codon
531 mutation was present in PGG1, PGG2 and PGG3 isolates whereas, a mutation at codon
526 was observed in one PGG1 group EAI3-IND isolate. Mutations at codons 515 and 516
were present concurrently in each case, in CAS and Orphan strains.
Twenty-two XDR-TB isolates with compensatory mutations in rpoC and rpoA genes had
the low fitness cost mutation rpoB S531L. One isolate with the rpoB H526R mutation had two
rpoC SNPs. In all, we observed 15 different rpoC SNPs and one rpoA SNP. The most common
was rpoC A172V which present in 5 isolates and rpoC P601L which was present in 3 isolates.
Polymorphisms at codon 463 of katG were observed among all the PGG1 isolates. Resis-
tance to isoniazid could be attributed to the katG codon in 34/37 of cases and most strains
(86%) had low fitness cost mutation, katG S315T while, two strains had katG S315N. Two
strains had a inhA S94A mutation in the absence of katGmutations. We did not observe any
inhA promoter mutations amongst the XDR isolates studied. One EAI3-lineage strain had a
katG Y413H change.
In summary, if rifampcin and isoniazaid resistance were tested in these XDR strains using
only MDR hot-spot region based targets (rpoB, katG and -15 region inhA), 100% of rifampicin
and 89% of isoniazid resistance would be detected.
Drug Resistance Conferring Mutations in XDR TB Strains from Pakistan
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Fig 1. Comparative drug resistance genes information ofMycobacterium tuberculosis study isolates.Circos plot ofMycobacterium tuberculosis
highlighting the genomic regions (Rv) where drug resistance associated SNPs were identified (colour coded in blue). The 5 inwards tracks represent SNP
density, Non-synonymous/synonymous densities, small insertion/deletions densities, large deletion density and uniqueness track.
doi:10.1371/journal.pone.0117771.g001
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When additional isoniazid resistance associated genes were analysed we found the oxyR
g142a nucleotide substitution to be present in 4 strains together with a katG S315T mutation
(S2 Dataset). The EAI3 lineage strain (with katG Y413H) had the mutations oxyR g38a, accD
M439I and A142V; in addition to rpoB H526R, and rpoC A172V and P601L mutations. We
also observed additional SNPs present only in resistant strains with a katG S315T mutation;
Rv1592C (G9D, n = 4), ndh L104F and E360K, Rv2242 (A156V), fabD (A3T), accD (E224D
and A243V), fadE24 (Q85R), nat (T175A).
Polymorphisms conferring resistance to pyrazinamide
All of the XDR strains were resistant to pyrazinamide treatment (Table 1). Non-synonymous
SNPs in the pncA gene were observed in 14 (38%) strains, whereby 11 different SNPs were ob-
served (S2 Dataset). Twenty-three pyrazinamide resistant isolates did not reveal any nsSNP in
pncA; two such strains had the rpsAmutation Q1228R.
Both pyrazinamide and isoniazid are pro-drugs which are converted to their active forms by
enzymatic activity within the mycobacterium. We explore an association between isoniazid
and pyrazinamide resistance by comparing katG and pncAmutations within strains. Of the
XDR strains, thirteen had pncA and katG S315T mutations, while one strain with a pncAmuta-
tion had inhA S94A (Table 1).
Polymorphisms in the genes for ethambutol resistance
All of the XDR strains were resistant to ethambutol. The ethambutol-resistance determining
region (ERDR) is primarily in the embB gene and we found that 23 strains to have embB codon
306 mutations, where M306I was most common (Table 2). Based on this data, commercial
Fig 2. Circular phylogram based on the polymorphisms in the drug resistance genes ofMycobacterium tuberculosis isolates.Maximum likelihood
analyses were performed with single nucleotide polymorphism identified in the drug resistance genes using Dendroscope software, version 3.2.8. Scale bar
indicates 1% nucleotide divergence in the genes. Branch length corresponds to number of genetic polymorphisms inferred.
doi:10.1371/journal.pone.0117771.g002
Drug Resistance Conferring Mutations in XDR TB Strains from Pakistan
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molecular diagnostic assays targeting embB codon 306 would detect ethambutol resistance in
62% of the XDR strains studied here.
Other ethambutol resistant strains had SNPs at embB codon 1024 (n = 4), codon 497 (n = 3),
codon 406 (n = 1), codon 378 (n = 3), codon 328 (n = 1) and codon 72 (n = 1), S2 Dataset.
We analyzed additional genes associated with ethambutol resistance; embC, embA, Rv3124,
rmlD, iniA, iniB, iniC and PPE49. Different combinations of SNPs were observed in these
ethambutol-resistance associated genes possibly, as compensatory mutations and or lineage as-
sociated mutations. Two EAI3-IND isolates (X5 and X32) had a distinct combination of
mutations; embB M306V, E378A and G406A, embA P913S, embC T270I, N394E, rmlD S257P
and iniA H481Q (S2 Dataset). Two Orphan isolates (X17 and X57) also had a distinct combi-
nation of mutations; embB E378A, embA P913S, embC T270I, N394E, rmlD S257P, iniA
H481Q, iniC R481C and PPE49 M67L. Another isolate had a SNP in Rv3124 (V273I) (S2 Data-
set) while one strain displayed a single nucleotide (T) deletion at codon 173 of iniA gene at
519 position.
Polymorphisms conferring resistance to streptomycin
The mechanism of streptomycin resistance in the XDR strains was investigated by analyzing
sequences of the ribosomal genes rpsL, rrs (500 region) and gidB. The rpsL mutation K43R was
found in 41% of streptomycin resistant isolates; this SNP was found independently (n = 11)
and also in combination with rrs A514C (n = 2), Table 3. The rpsL mutation K88R was found
in combination with rrs A906G and gidB P75S. Three strains had rrs A514C mutations
only. There were eight different SNPs in gidB. Eight streptomycin resistant strains had gidB
Fig 3. Process for identification of SNPs in genes associated with drug resistance. The flow diagram describes the manner in which SNPs were
identified for inclusion in the prepared Tables.
doi:10.1371/journal.pone.0117771.g003
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mutations only, without rpsL and rrs (500 region) SNPs. However, six streptomycin resistant
and five sensitive strains were without mutations in rrs, rpsL or gidB (S2 Dataset).
Polymorphisms in the genes for fluoroquinolone resistance
Mutations in gyrA and gyrB genes were analysed to investigate flouroquinolone resistance in
the XDR strains. The most common mutation in the quinolone-resistance determining region
(QRDR) of gyrA gene covering codons 90–98 was A94G, followed by A90V and A94Y
(Table 4). All CAS family strains had gyrA QRDR mutations. One X3 strain had gyrA D94Y
together with gyrB T500N. In total, 81% of isolates had SNPs in the QRDR of gyrA, which is
the target region in currently available commercial diagnostic assays for flouroquinolone
resistance.
Table 1. SNPs leading to rifampicin, isoniazid and pyrazinamide resistance in XDR strains.
Lineage of XDR isolates rpoB# RIF Compensatory mutations katG INH compensatory mutations pncA No.
CAS1-Delhi S531L rpoC G433S S315T P69G 1
CAS1-Delhi (1), Orphan
(1)
S531L rpoC G433S S315T 2
CAS S531L rpoC P434L, S94A 2
EAI3-IND S531L rpoC A172V, rpoC Q435A, rpoC
P601L
S315T I5T 1
CAS1-Delhi S531L rpoC V1252L S315T V41
stop
1
CAS1-Delhi S531L rpoC L516P S315T 2
Orphan S531L rpoC A172V, rpoC G332R S315T P62S 2
CAS1-Delhi S531L rpoC L507V, rpoC R741C S315T 1
CAS1-Delhi S531L rpoC V483G S315T 1
X3 S531L rpoC G594E S315T I6M 1
CAS1-Delhi S531L rpoC A492P S315T 1
Orphan S531L rpoC A172V, rpoC P601L S315T M175T 1
CAS1-Delhi S531L rpoC V483A S315T 2
CAS1-Delhi S531L S94A D63H 1
T1 S531L rpoA D324Y S315T P54L 2
CAS1-Delhi S531L S315T 1
CAS1-Delhi (1), T1 (1) S531L rpoC N416S S315T 2
Orphan M515I,
D516Y
S315T T76P 2
CAS1-Delhi M515I,
D516Y
S315T Q141P 1
CAS1-Delhi (1), Orphan
(1)
M515I,
D516Y
S315T 2
CAS2 D516Y S315T V130M 1
CAS1-Delhi D516Y S315T 2
Cas1-Delhi (1), Orphan (1) D516V S315T 2
CAS1-Delhi D516V S315N 2
EAI3-IND H526R rpoC A172V, rpoC P601L Y413H oxyR g38a, accD M439I, accD
A142V
1
All strain were resistant to rifampicin (RIF, 1 μg/ml), isoniazid (INH, 1 μg/ml) and pyrazinamide (PZA, 100μg/ml). ‘#’ mutations in the rifampicin- resistance
determining region (RRDR), the number in parenthesis indicates the number of MTB isolates from lineage
doi:10.1371/journal.pone.0117771.t001
Drug Resistance Conferring Mutations in XDR TB Strains from Pakistan
PLOS ONE | DOI:10.1371/journal.pone.0117771 February 26, 2015 9 / 17
Polymorphism at codon 95 of gyrA was observed among PGG1 and PGG2 isolates (S2
Dataset). The gyrA, G668D polymorphism was present in PGG3 (n = 3) isolates belonging to
T1 lineage.
Of the eight strains which did not have gyrA QRDR SNPs, four had SNPs in the gyrB gene.
One T1 strain only had the gyrB S447F mutation, two EAI3 strains only had the M291I mutation
and an Orphan isolate had a gyrB M291I and A432Vmutations. In one strain, a three nucleotide
deletion was observed at codon 683 of gyrB gene at 7158 position. In all, four CAS1-Delhi XDR
strains without gyrA or gyrB mutations.
Table 2. SNPs in genes conferring resistance ethambutol.
Lineage of XDR isolate Phenotype* embB No. of specimens
CAS1-Delhi (9), Orphan (3), T1 (1) R M306I 13
Cas1-Delhi (5), T1 (2) R M306V 7
Cas1-Delhi R M306L 1
EAI3-IND R M306V, E378A, G406A 2
CAS2 R D354A, Q497P 1
X3 R D328Y 1
Orphan R E378A 3
CAS1-Delhi R G406A 1
CAS R Q497K 2
Orphan R I72L # 1
CAS1-Delhi (3), Orphan (1) R D1024T # 4
CAS1-Delhi R wt # 1
‘*’ strains were tested against resistant to ethambutol (5 μg/ml),
‘#’ mutation outside the embB ethambutol resistance determining region (ERDR), the number in parenthesis indicates the number of MTB isolates from
each lineage
doi:10.1371/journal.pone.0117771.t002
Table 3. Combination of SNPs in genes conferring resistance to streptomycin.
Lineage of XDR isolates Phenotype* rpsL rrs (500
region)
gidB Number of
specimens
Percentage of resistant isolates (n
= 32)
CAS1-Delhi (5), T1 (3), Orphan (3) R K43R 11 34
CAS1-Delhi R K43R A514C 1 3
Orphan R A514C 2 6
CAS1-Delhi R A514T 1 3
CAS1-Delhi R K43R A514C Q87 Stop 1 3
CAS1-Delhi R A906G W148
Stop
1 3
CAS R K88R A906G P75S 1 3
CAS1-Delhi R G71 Stop 2 6
CAS (1), X3 (1) R P75S 2 6
CAS1-Delhi R W45 Stop 1 3
Orphan R A82P 1 3
CAS2 R A119D 1 3
CAS1-Delhi (6), EAI3-IND (1) R 6 19
CAS1-Delhi (2), Orphan (2), EAI3-
IND (1)
S 5
‘*’ strains resistant to streptomycin (STR, 2 μg/ml), the number in parenthesis indicates the number of MTB isolates from each lineage
doi:10.1371/journal.pone.0117771.t003
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Polymorphisms conferring resistance to aminoglycosides
To investigate the mechanism for aminoglycoside resistance codon 1400 region of the rrs gene
was analysed. Thirteen XDR strains were resistant to all three aminoglycosides (amikacin, kana-
mycin and capreomycin). Twenty-four XDR strains were resistant to amikacin and kanamycin
but sensisitive to capreomycin. The most common rrsmutation across lineages was A1401G. Of
strains resistant to amikacin, kanamycin and capreomysin, eleven had the SNP rrs A1401G and
one had G1484T, whilst 2 strains had no mutation in the 1400 region of rrs (Table 5). Of the
strains resistant to amikacin and kanamycin, eighteen had the SNP A1401G whilst five did not
have a SNP in the rrs 1400 region. As current commercial diagnostic assays for aminoglycoside
resistance target rrs nt 1401, 78% of resistance would be detected in these XDR isolates.
In all, 6 aminoglycoside resistant isolates did not reveal any polymorphism in hyper-vari-
able 1400 region of rrs gene (S2 Dataset).
Polymorphisms in the genes for ethionamide resistance
Five XDR isolates resistant to ethionamide but none showed any polymorphism in ethA gene,
but one one ethionamide resistant isolate had the mutation ethA R239G which was also present
in an ethionamide sensitive isolate (S2 Dataset).
Table 4. Combination of SNPs in genes conferring resistance to ﬂuoroquinolone.
Lineage of XDR isolates gyrA# gyrB Number of specimens
CAS1-Delhi (9), CAS2 (1) D94G 10
Orphan D94G M291I 2
Orphan (5), CAS1-Delhi (3), T1 (1) A90V 9
CAS1-Delhi (2), CAS (2) D94Y 4
CAS1-Delhi A90V, D94Y 1
CAS1-Delhi S91P 1
T1 D94N 1
X3 D94Y T500N 1
T1 S447F 1
EAI3-IND M291I 2
Orphan M291I, A432V 1
CAS1-Delhi 4
All strains were resistant to ciproﬂoxacin (2μg/ml) and oﬂoxacin (2 μg/ml). ‘#’ mutations in the gyrA
quinolone- resistance determining region (QRDR), the number in parenthesis indicates the number of MTB
isolates from each lineage
doi:10.1371/journal.pone.0117771.t004
Table 5. SNPs present in XDR strains related to aminoglycoside resistance.
Phenotypic data* Genotypes rrs (1400 region) Number of specimens
R to AMK, KAN, CAP CAS1-Delhi (6), T1 (2), Orphan (2), X3 (1) A1401G 11
Orphan G1484T 1
EAI3-IND (1), CAS1-Delhi (1) wt 2
R to AMK, KAN CAS2(1), CAS1-Delhi (11), CAS (2), EAI3-IND (1), Orphan (3) A1401G 18
CAS1-Delhi (3), Orphan (1), T1(1) wt 5
‘*’ resistance determined at amikacin (AMK, 6 μg/ml), kanamycin (KAN, 6 μg/ml) and capreomycin (CAP, 6 μg/ml), ‘wt’ wild type indicates absence of
SNPs in the rrs 1400 gene, the number in parenthesis indicates the number of MTB isolates from each lineage
doi:10.1371/journal.pone.0117771.t005
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Discussion
Our results present the first WGS based characterization of XDR-TB strains from Pakistan. We
focused on SNPs in genes known to confer resistance to first- and second-line drugs and pres-
ent data relevant to molecular diagnostic assays for drug susceptibility testing.
Consistent with published reports all the rifampicin resistant MTB isolates in this study re-
vealed at least one rpoB gene codon mutation i.e. 531, 526, 516 or 515, in the RRDR region
[35,36,37,38]. The most common mutation was the rpoB S531L, corroborating with previous
reports [33]. In 22/23 isolates, compensatory mutations in rpoC and rpoA genes were coinci-
dent with the low fitness cost rpoB531 mutation, supporting previous reports which demon-
strate increased fitness in rifampicin resistant isolates as a consequence of these compensatory
mutations [39,40,41]. One EAI lineage isolate had the rpoB H526R mutation together with two
rpoCmutations. As the rpoB codon 526 mutation has been shown to have a higher fitness cost
than the codon 531 mutation [17] therefore, it would be an advantage for such an isolate to ac-
cumulate the rpoC compensatory mutations.
Based on the katG463-gyrA95 polymorphism 91% of the MTB isolates belonged to PGG1 of
which the majority were CAS family isolates, as previously reported [30]. PGG1 is considered
the oldest of MTB lineages and has been previously been reported from Asia [42]. The predom-
inance of CAS strains suggests that they are well adapted to human populations in this region
[43,44,45,46].
The most frequently observed isoniazid resistance associated mutation observed in our
strains was katG S315T, which has previously been shown to be associated with a growth ad-
vantage in strains [47]. Three isolates with inhA codon 94 mutations did not reveal katG315
mutations, supporting a causal relationship of this mutation for isoniazid resistance [48,49].
Pyrazinamide is important as a first-line anti-tuberculous drug but phenotypic and genotypic
discordance exists regarding testing its drug susceptibility. Consistent with previous reports, we
found that more than 50% of resistant isolates did not reveal any mutation in pncA gene [50].
Mutations in pncA gene are thought to be the primary mechanism for pyrazinamide resistance,
but our data consistent with others indicates that other resistance mechanisms may exist [51].
We found rpsAmutations in two XDR isolates which did not have pncAmutation, suggesting
that this gene may play a role in resistance to pyrazinamide [52]. Additional pyrazinamide resis-
tant strains had neither pncA nor rpsAmutations, and further supports the suggestion that mech-
anisms such an efflux pump for pncA wild type resistant MTB isolates may be relevant [53].
The embB306 SNP was found to be the most common mutation associated with ethambutol
resistance in MTB strains, as reported previously [54]. The embB306 mutation has been shown
to be associated with high-level ethambutol resistance [55]. In addition, we also observed embB
codon 378, 406 and 497 mutations; which have reported previously [56] [55,57]. Our observa-
tions of distinct combinations of embB and compensatory mutations in XDR isolates of EAI-
IND and Orphan types suggest that some of these may lineage associated mutations. Especially,
we observed a particular pattern of embB, embA, embC, rmlD and inimutations was in four
Orphan types, of which three were resistant and one was sensitive to ethambutol.
The most common streptomycin resistance associated mutation we observed was rspL
K43R. This mutation has been shown to play a role in reduced fitness cost and enhanced
growth rate of resistant MTB isolates [47]. The K43R mutation has also been associated with
high-level streptomycin resistance [58]. In the rrs gene we identified point mutations at posi-
tions 514 and 906, encoding for streptomycin resistance [58,59]. Previous studies have reported
role of gidB polymorphism for low level of streptomycin resistance in MTB [60]. Here we
found eight different gidB SNPs. Three strains had compensatory gidB SNPs with rpsL and/or
rrsmutations. Six streptomycin resistant isolates had gidB SNPs but did not have either rpsL or
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rrs gene mutations. The occurrence of gidB mutations in strains reduces drug pressure for se-
lection of highly resistant isolates, therefore it has been suggested that high-level streptomycin
resistant strains (e.g. rpsL mutants) arise more frequently in gidB mutants than in wild-type
cells [61]. We observed six streptomycin resistant strains without mutations in rpsL, rrs or
gidB. The aminoglycoside antibiotics inhibit protein translation therefore it is likely that in ad-
ditional mutations may be relevant for inactivating the effect of streptomycin in inhibiting
tRNA translocation in mycobacteria.
In the strains resistant to amikacin, kanamycin and capreomycin we found 16S rRNA gene
rrs1401 and 1484 mutations to be the most common. These rrsmutations have previously been
associated kanamycin and capreomycin [39,56,62]. In addition, it has been shown that the tlyA
and rrs gene mutations jointly play a role for capreomycin resistance [63]. However, we did not
observe any tlyA mutations amongst our strains.
We found that across MTB lineages, the most common fluoroquinolone resistance associat-
ed mutation was at gyrA codon 94, as shown previously [56,64]. Lineages other than CAS (X3,
T1, EAI and Orphan) had gyrB SNPs in the 400 region. The gyrB gene has previously been
shown to result in flouroquinolone resistance [65]. Four XDR strains did not have gyrA or gyrB
mutations. This may be explained by the fact that additional mechanisms such as efflux pumps
may be involved in a generating resistance flouroquinolone [66]. The predominant lineage
amongst our XDR isolates was CAS and there is less representation of the other strain types.
However, this data is suggestive of the association of flouroquinolone resistance in CAS line-
ages with gyrA QRDR region.
In the case of ethionamide, we found that none of the isolates had ethA SNPs which were
particular to ethionamide resistance, as one isolate had ethA R239G mutation which was also
present in an ethionamide sensitive isolate. A low frequency of mutation in ethA gene of eth-
ambutol resistant isolates have also been reported earlier and may suggest existence of some
other mechanisms such as efflux pump for ethionamide resistance [56,67].
Overall, the most frequently seen drug resistance mutations observed for isoniazid, rifampi-
cin, streptomycin, ethambutol, aminoglycosides and ofloxacin were katG315, rpoB531, rpsL43,
embB306, rrs1401 and gyrA94 respectively as previously reported [35,36,37,38,55,56,68,69].
Currently available commercial assays for detection of drug resistance (MTBDRplus and
MTBDRsl) target the rpoB531, 516 and 526, katG315, gyrA94, 91 and 90 and rrs1401 regions.
Based on our data the frequency of drug resistance detection using such assays for these strains
would have been 100% for rifampicin resistance, 92% for isoniazid resistance, 81% for fluoro-
quinolone resistance, 78% for aminoglycoside and 62% for ethambutol resistance. Our data in-
dicates that SNPs in drug resistance genes vary with different MTB lineages. Therefore, it
highlights the relevance for WGS data from prevalent global strain types in order to develop
improved molecular diagnostic assays for resistance in MTB. Additional knowlegde of muta-
tions that are compensatory to those that confer drug resistance will be important for predic-
tion of levels of drug resistance and therefore, to guide treatment of drug resistance isolates.
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